Detalhe da pesquisa
1.
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
J Infect Dis
; 228(6): 734-741, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210741
2.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
J Infect Dis
; 225(10): 1741-1749, 2022 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35301540
3.
Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067.
Stat Med
; 41(6): 1120-1136, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35080038
4.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
N Engl J Med
; 388(9): 857-859, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734884
5.
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
Clin Infect Dis
; 70(2): 319-322, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31125395
6.
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
AIDS Behav
; 24(9): 2520-2531, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32052214
7.
The Longitudinal Effects of Non-injection Substance Use on Sustained HIV Viral Load Undetectability Among MSM and Heterosexual Men in Brazil and Thailand: The Role of ART Adherence and Depressive Symptoms (HPTN 063).
AIDS Behav
; 23(3): 649-660, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30725397
8.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS Med
; 15(11): e1002690, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408115
9.
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Vaccine
; 41(29): 4280-4286, 2023 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271706
10.
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
Vaccine
; 41(41): 5965-5973, 2023 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37652823
11.
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Expert Rev Vaccines
; 22(1): 501-517, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246757
12.
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 22(11): 1565-1576, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35963274
13.
Correction to "Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study".
ACS Pharmacol Transl Sci
; 4(4): 1462, 2021 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35783008
14.
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
ACS Pharmacol Transl Sci
; 4(1): 226-239, 2021 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33615175
15.
Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
J Acquir Immune Defic Syndr
; 85(1): 93-97, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452972
16.
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Lancet HIV
; 7(7): e472-e481, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497491
17.
Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).
PLoS One
; 11(12): e0167629, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27936098